Multifactorial effects of vildagliptin added to ongoing metformin therapy in patients with type 2 diabetes mellitus

Pharmacological Reports

Volumn 67, Issue 1, 2015, Pages 24-31

  Strózik, Agnieszka ^a   Stęposz, Arkadiusz ^a   Basiak, Marcin ^a   Drozdz, Magdalena ^a   Okopień, Boguslaw ^a  

^a MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Diabetes; DPP IV inhibitors; Glycaemic control; Lipid profile; Metformin

Indexed keywords

ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTITHROMBOCYTIC AGENT; C REACTIVE PROTEIN; CHOLESTEROL; CYTOKINE; GLUCOSE; HEMOGLOBIN A1C; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; INTERLEUKIN 1BETA; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR ALPHA; VILDAGLIPTIN; ADAMANTANE; ANTIDIABETIC AGENT; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LIPID; NITRILE; PYRROLIDINE DERIVATIVE;

ADULT; AGED; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DIABETIC PATIENT; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TOLERABILITY; FEMALE; GASTROINTESTINAL DISEASE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGLYCEMIA; INCIDENCE; INSULIN BLOOD LEVEL; LIPID METABOLISM; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; METABOLIC REGULATION; NON INSULIN DEPENDENT DIABETES MELLITUS; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; ANALOGS AND DERIVATIVES; BLOOD; BLOOD PRESSURE; BODY MASS; COMBINATION DRUG THERAPY; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; DRUG EFFECTS; METABOLISM; MIDDLE AGED;

ADAMANTANE; ADULT; AGED; BLOOD GLUCOSE; BLOOD PRESSURE; BODY MASS INDEX; CHOLESTEROL, LDL; CYTOKINES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; LIPIDS; MALE; METFORMIN; MIDDLE AGED; NITRILES; PYRROLIDINES;

EID: 84908374091     PISSN: 22995684     EISSN: 22995684     Source Type: Journal    
DOI: 10.1016/j.pharep.2014.07.016     Document Type: Article

References (21)

1. Pruski M, Krysiak R, Okopien B. Pleiotropic actionofshort-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia. Diabetes Care 2009;32:1421-4.
2. Green J, Feinglos M. Update on type 2 diabetes mellitus: understanding changes in the diabetes treatment paradigm. Int J Clin Pract 2007;61(154):3-11.
3. Lamanna C, Monami M, Marchionni N, Mannucci E. Effect of metformin on cardiovascular events and mortality: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 2011;13(3):221-8.
4. Franek E, Gajos G, Gumprecht J, Kretowski A, Zahorska-Markiewicz B, Malecki MT. The role of glucagon-like peptide 1 in glucose homeostasis and in other aspects of human physiology. Pol Arch Med Wewn 2009;119(11):743-51.
5. Garber AJ, Sharma MD. Update: vildagliptin for the treatment of Type 2 diabetes. Expert Opin Investig Drugs 2008;17(1):105-13.
6. Ahren B, Pacini G, Foley JE, Schweizer A. Improved meal related beta cell function and insulin sensitivity by the dipeptidyl peptidase IV inhibitor vildagliptin in metformin treated patients with type 2 diabetes over 1 year. Diabetes Care 2005;28:1936-40.
7. Bolli G, Dotta F, Colin L, Minic B, Goodman M. Comparison of vildagliptin and pioglitazone in patients with type 2 diabetes inadequately controlled with metformin. Diabetes Obes Metab 2009;11(6):589-95.
8. Bosi E, Camisasca RP, Collober C, Rochotte E, Garber AJ. Effects of vildagliptin on glucose control over24weeks inpatients with type2 diabetes inadequately controlled with metformin. Diabetes Care 2007;30(4):890-5.
9. Filozof C, Gautier JF. A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52-week, randomized study. Diabet Med 2010;27(3):318-26.
10. Maida A, Lamont BJ, Cao X, Drucker DJ. Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-a in mice. Diabetologia 2011;54(2):339-49.
11. Mannucci E, Ognibene A, Cremasco F, Bardini G, Mencucci A, Pierazzuoli E, et al. Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. Diabetes Care 2001;24(3):489-94.
12. McGill JB. Impact of incretin therapy on islet dysfunction: an underlying defect in the pathophysiology of type 2 diabetes. Postgrad Med 2009;121(1):46-58.
13. Meece J. Pancreatic islet dysfunction in type 2 diabetes: a rational target for incretin-based therapies. Curr Med Res Opin 2007;23(4):933-44.
14. Duttaroy A, Voelker F, Merriam K, Zhang X, Ren X, Subramanian K, et al. The DPP-4 inhibitor vildagliptin increases pancreatic beta cell mass in neonatal rats. Eur J Pharmacol 2011;650(2-3):703-7.
15. Lopes-Virella MF, Virella G. Diabetes et atherosclerosis. In: Johnstone MT, Vaves A, editors. Diabetes and cardiovascular disease. 2nd ed., New York City: Humana Press; 2005. p. 225-50.
16. Libby P, Ridker PM, Hansson GK. Leducq transatlantic network on atherothrombosis: inflammation in atherosclerosis from pathophysiology to practice. J Am Coll Cardiol 2009;54:2129-38.
17. Maiti R, Agrawal NK. Atherosclerosis in diabetes mellitus: role of inflamation Indian. J Med Sci 2007;61(5):292-306.
18. Okopień B, Krysiak R, Kowalski J, Madej A, Belowski D, Zieliński M, et al. Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates. J Cardiovasc Pharmacol 2005;46:377-86.
19. Okopień B, Kowalski J, Krysiak R, Łabuzek K, Stachura-Kułach A, Kułach A, et al. Monocyte suppressing action of fenofibrate. Pharmacol Rep 2005;57:367-72.
20. Gü rlek A, Bayraktar M, Kirazli S. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels. Diabetes Care 2000;23(1):88-92.
21. Kozek E, Klupa T, Małecki M. Fibrinogen as a coronary risk factor in patients with type 2 diabetes mellitus. Diabet Prakt 2003;4(4):265-71.